Plant ID: NPO29861
Plant Latin Name: Aconitum carmichaeli
Taxonomy Genus: Aconitum
Taxonomy Family: Ranunculaceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
707241-1
Vietnam; China
HTR2B; HTR2A; DRD3; HTR2C; DRD2; DRD4; | |
TSHR; | |
CA2; CA3; CA1; CA7; CA12; CA14; CA9; | |
HSD17B10; | |
HIF1A; | |
LMNA; |
Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.296E-13 | 1.248E-09 | CA1, CA12, CA2, CA3, CA7, CA9 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.694E-10 | 4.512E-07 | CA2, CA7, DRD2, DRD3, HTR2A, HTR2B, HTR2C |
BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 1.972E-09 | 2.147E-06 | DRD2, DRD3, DRD4, HTR2A |
BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 5.656E-09 | 5.355E-06 | HTR2A, HTR2B, HTR2C |
MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 3.162E-08 | 2.374E-05 | DRD2, DRD3, DRD4 |
BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 5.982E-08 | 3.520E-05 | DRD2, HTR2A, HTR2B, HTR2C |
BP | GO:0009987; cellular process | GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway | 6.769E-08 | 3.779E-05 | DRD2, DRD3, DRD4 |
BP | GO:0050896; response to stimulus | GO:0034776; response to histamine | 9.302E-08 | 4.560E-05 | DRD2, DRD3, DRD4 |
BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 9.302E-08 | 4.560E-05 | DRD2, DRD3, HTR2B |
MF | GO:0005488; binding | GO:0051378; serotonin binding | 9.302E-08 | 4.560E-05 | HTR2A, HTR2B, HTR2C |
MF | GO:0005488; binding | GO:0035240; dopamine binding | 1.611E-07 | 6.744E-05 | DRD2, DRD3, DRD4 |
BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 7.290E-07 | 2.301E-04 | HTR2A, HTR2C |
MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 7.290E-07 | 2.301E-04 | HTR2A, HTR2C |
BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 9.919E-07 | 2.833E-04 | DRD2, DRD3, DRD4 |
BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.133E-06 | 3.046E-04 | HTR2A, HTR2B, HTR2C |
MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.133E-06 | 3.046E-04 | HTR2A, HTR2B, HTR2C |
BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 1.454E-06 | 3.724E-04 | DRD2, DRD3, DRD4 |
BP | GO:0008152; metabolic process | GO:0042417; dopamine metabolic process | 1.830E-06 | 4.477E-04 | DRD2, DRD3, DRD4 |
BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 1.830E-06 | 4.477E-04 | DRD2, DRD3, HTR2A |
BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 2.186E-06 | 5.011E-04 | DRD2, DRD3 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.186E-06 | 5.011E-04 | CA2, CA7 |
BP | GO:0023052; signaling | GO:0051586; positive regulation of dopamine uptake involved in synaptic transmission | 2.186E-06 | 5.011E-04 | DRD2, DRD4 |
BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 2.764E-06 | 6.024E-04 | DRD2, DRD3, DRD4 |
BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 7.279E-06 | 1.277E-03 | DRD2, DRD3 |
BP | GO:0007610; behavior | GO:0008542; visual learning | 9.556E-06 | 1.553E-03 | DRD2, DRD3, HIF1A |
BP | Unclassified; | GO:0032415; regulation of sodium:proton antiporter activity | 1.091E-05 | 1.710E-03 | DRD3, DRD4 |
MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.091E-05 | 1.710E-03 | CA1, CA2 |
BP | GO:0050896; response to stimulus | GO:0009628; response to abiotic stimulus | 1.249E-05 | 1.929E-03 | CA2, DRD2, DRD3, HIF1A, HTR2A, HTR2B, LMNA |
BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 1.545E-05 | 2.304E-03 | DRD2, DRD3, DRD4, HTR2C |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 2.251E-05 | 3.268E-03 | DRD2, HTR2A, HTR2B, HTR2C |
BP | GO:0009987; cellular process | GO:0007189; adenylate cyclase-activating G-protein coupled receptor signaling pathway | 3.252E-05 | 4.392E-03 | DRD2, DRD3, TSHR |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 3.267E-05 | 4.392E-03 | CA2, CA7 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.532E-05 | 5.805E-03 | CA1, CA12, CA2, CA3, CA7, CA9 |
BP | GO:0051179; localization | GO:0002028; regulation of sodium ion transport | 4.981E-05 | 6.198E-03 | DRD2, DRD3, DRD4 |
BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 5.654E-05 | 6.728E-03 | DRD2, DRD3 |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 5.654E-05 | 6.728E-03 | CA2, CA7 |
BP | GO:0032501; multicellular organismal process | GO:0035815; positive regulation of renal sodium excretion | 5.654E-05 | 6.728E-03 | DRD2, DRD3 |
BP | GO:0007610; behavior | GO:0048149; behavioral response to ethanol | 6.593E-05 | 7.596E-03 | DRD2, DRD4 |
BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 6.593E-05 | 7.596E-03 | DRD2, HTR2A |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.271E-19 | 1.365E-14 | CA1, CA12, CA14, CA2, CA3, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.686E-15 | 4.013E-11 | CA1, CA12, CA14, CA2, CA3, CA7, CA9 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.097E-04 | 1.142E-02 | DRD2, DRD3, DRD4, HTR2A, HTR2B, HTR2C, TSHR |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 5.409E-04 | 3.952E-02 | CA2, CA9, TSHR |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.484E-18 | 5.195E-17 | CA12, CA1, CA3, CA2, CA7, CA9, CA14 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.566E-09 | 2.740E-08 | HTR2B, HTR2C, HTR2A, DRD2, DRD3, DRD4, TSHR |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 7.971E-07 | 9.299E-06 | HTR2B, HTR2C, HTR2A, DRD2 |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.380E-05 | 6.458E-04 | HTR2B, HTR2C, HTR2A |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.098E-04 | 7.685E-04 | HTR2B, HTR2C, HTR2A |
09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 1.669E-04 | 9.733E-04 | DRD2, DRD3, DRD4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 4.443E-04 | 2.221E-03 | HTR2B, HTR2C, HTR2A |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.214E-02 | 5.313E-02 | DRD2, TSHR |
09150 Organismal Systems | 09155 Excretory system | hsa04966 | Collecting duct acid secretion | 2.271E-02 | 7.949E-02 | CA2 |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.938E-02 | 7.536E-02 | CA2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR2C; |
NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR2A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD3; HTR2A; HTR2C; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR2C; |
K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; HTR2C; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; HTR2C; |
NA: NA | Addiction | NA | HTR2A; |
A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2A; HTR2C; |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2B; HTR2C; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; HTR2C; |
I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | HTR2A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR2C; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD3; HTR2C; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A; HTR2B; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; |
I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; |
NA: NA | Primary insomnia | NA | HTR2C; |